Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 205

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

The metabolism and bioavailability of morphine in patients with severe liver cirrhosis.

Open access
Hasselstrom, J, Eriksson, S, Persson, A, Rane, A, Svensson, JO, Sawe, J · 1990 · British Journal of Clinical Pharmacology

Abstract

1. The oral and intravenous kinetics of morphine were investigated in seven cirrhotic patients with a history of encephalopathy. The plasma concentrations of morphine and its metabolites morphine‐3 (M3G) and morphine‐6 (M6G) were measured by h.p.l.c. 2. The mean terminal elimination half‐life of morphine was 4.2 h (95% CI 3.6‐4.8) the mean volume of distribution was 4.1 l kg‐1 (95% CI 2.9‐5.4) and the mean plasma clearance was 11.4 ml min‐1 kg‐1 (95% CI 8.1‐14.7). The mean oral bioavailability was 101% (95% CI 56‐147). 3. The plasma clearance of morphine was significantly lower, its terminal elimination half‐life longer and its oral bioavailability greater in the cirrhotic patients compared with patients with normal liver function. The metabolic ratio M3G/morphine was significantly lower in the cirrhotic patients than in control subjects after oral dosing, but did not differ after intravenous dosing. 4. The average urinary recoveries of morphine plus M3G and M6G were 49.9% after i.v. and 57.7% after oral administration. There were no statistically significant differences in the urinary recovery between the two routes of administration or between the cirrhotic patients and controls. 5. Specific changes in the EEG pattern could not be detected after intravenous dosage. 6. The metabolism of morphine is impaired significantly in patients with severe cirrhosis. Clinically important findings were a high oral bioavailability and a long elimination half‐life. These findings call for cautious dosing of oral and intravenous morphine in patients with severe end stage liver disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2125.1990.tb03638.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 205

Metadata

Authors
Hasselstrom, J., Eriksson, S., Persson, A., Rane, A., Svensson, J., & Sawe, J.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
1990-03
Volume
29
Issue
3
Pages
289-297
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W1985750268
Cited by
205
References
1
FWCI
5.04
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. https://app.cochat.ai/papers/10.1111/j.1365-2125.1990.tb03638.x
The paper
Hasselstrom, J., Eriksson, S., Persson, A., Rane, A., Svensson, J., & Sawe, J. (1990). The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.1990.tb03638.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.